• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 8:32:51 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $IRIX alert in real time by email
    SC 13G/A 1 d19444dsc13ga.htm SC 13G/A SC 13G/A

     

     

    fSCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.1)*

     

     

    IRIDEX CORPORATION

    (Name of Issuer)

    Common Stock, $0.01 par value

    (Title of Class of Securities)

    462684101

    (CUSIP Number)

    December 31, 2020

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. Beneficial ownership information contained herein is given as of the date listed above.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


      1    

      Names of Reporting Persons.

      North Tide Capital Master, LP

     

      I.R.S. Identification Nos. of above persons (entities only)

      2  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization.

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0 shares

       6   

      Shared Voting Power

     

      760,069 shares

      Refer to Item 4 below.

       7   

      Sole Dispositive Power

     

      0 shares

       8   

      Shared Dispositive Power

     

      760,069 shares

      Refer to Item 4 below.

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      760,069 shares

      Refer to Item 4 below.

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

      Not applicable.

    11  

      Percent of Class Represented by Amount in Row (9)

     

      5.5%

      Refer to Item 4 below.

    12  

      Type of Reporting Person (See Instructions)

     

      PN (Limited Partnership)

     


      1    

      Names of Reporting Persons.

      North Tide Capital GP, LLC

     

      I.R.S. Identification Nos. of above persons (entities only)

      2  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization.

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0 shares

       6   

      Shared Voting Power

     

      760,069 shares

      Refer to Item 4 below.

       7   

      Sole Dispositive Power

     

      0 shares

       8   

      Shared Dispositive Power

     

      760,069 shares

      Refer to Item 4 below.

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      760,069 shares

      Refer to Item 4 below.

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

      Not applicable.

    11  

      Percent of Class Represented by Amount in Row (9)

     

      5.5%

      Refer to Item 4 below.

    12  

      Type of Reporting Person (See Instructions)

     

      OO (Limited Liability Company)


      1    

      Names of Reporting Persons.

      North Tide Capital, LP

     

      I.R.S. Identification Nos. of above persons (entities only)

      2  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization.

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0 shares

       6   

      Shared Voting Power

     

      760,069 shares

      Refer to Item 4 below.

       7   

      Sole Dispositive Power

     

      0 shares

       8   

      Shared Dispositive Power

     

      760,069 shares

      Refer to Item 4 below.

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      760,069 shares

      Refer to Item 4 below.

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

      Not applicable.

    11  

      Percent of Class Represented by Amount in Row (9)

     

      5.5%

      Refer to Item 4 below.

    12  

      Type of Reporting Person (See Instructions)

     

      PN (Limited Partnership)


      1    

      Names of Reporting Persons.

      North Tide Capital, LLC

     

      I.R.S. Identification Nos. of above persons (entities only)

      2  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization.

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0 shares

       6   

      Shared Voting Power

     

      760,069 shares

      Refer to Item 4 below.

       7   

      Sole Dispositive Power

     

      0 shares

       8   

      Shared Dispositive Power

     

      760,069 shares

      Refer to Item 4 below.

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      760,069 shares

      Refer to Item 4 below.

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

      Not applicable.

    11  

      Percent of Class Represented by Amount in Row (9)

     

      5.5%

      Refer to Item 4 below.

    12  

      Type of Reporting Person (See Instructions)

     

      OO (Limited Liability Company)


      1    

      Names of Reporting Persons.

      Conan Laughlin

     

      I.R.S. Identification Nos. of above persons (entities only)

      2  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization.

     

      United States citizen

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0 shares

       6   

      Shared Voting Power

     

      760,069 shares

      Refer to Item 4 below.

       7   

      Sole Dispositive Power

     

      0 shares

       8   

      Shared Dispositive Power

     

      760,069 shares

      Refer to Item 4 below.

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      760,069 shares

      Refer to Item 4 below.

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

      Not applicable.

    11  

      Percent of Class Represented by Amount in Row (9)

     

      5.5%

      Refer to Item 4 below.

    12  

      Type of Reporting Person (See Instructions)

     

      IN


    Item 1.

     

     

      (a)

    Name of Issuer

    Iridex Corporation

     

      (b)

    Address of Issuer’s Principal Executive Offices

    1212 Terra Bella Avenue

    Mountain View

    California 94043

    Item 2.

     

      (a)

    Name of Person Filing

    This Amendment No. 1 to the Schedule 13G (this “Amendment”) is being filed by North Tide Capital Master, LP (the “Fund”), North Tide Capital GP, LLC (the “Fund General Partner”), North Tide Capital, LP (the “Investment Manager”), North Tide Capital, LLC (the “General Partner”), and Conan Laughlin, who are collectively referred to as the “Reporting Persons.” Conan Laughlin is the sole manager of the General Partner and the Fund General Partner. The General Partner is the sole general partner of the Investment Manager, which is the investment manager of the Fund. The Fund General Partner is the sole general partner of the Fund. The Reporting Persons have entered into a Joint Filing Agreement, dated as of the date hereof, a copy of which is filed with this Schedule 13G as Exhibit 99.1 (which is incorporated herein by reference), pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k) under the Act.

     


      (b)

    Address of Principal Business Office or, if none, Residence

    The principal business office of the Reporting Persons with respect to the shares reported hereunder is 8 Newbury Street, 4th Floor, Boston, Massachusetts 02116.

     

      (c)

    Citizenship

    North Tide Capital Master, LP—Delaware

    North Tide Capital, LP – Delaware

    North Tide Capital, LLC – Delaware

    Mr. Laughlin – United States citizen

     

      (d)

    Title of Class of Securities

    Common Stock, $0.01 par value

     

      (e)

    CUSIP Number

    462684101

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)

      

    []

       Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

    (b)

      

    []

       Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

    (c)

      

    [ ]

       Insurance Company as defined in Section 3(a)(19) of the Act

    (d)

      

    [ ]

       Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

    (e)

      

    [ ]

       An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

    (f)

      

    [ ]

       An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

    (g)

      

    [ ]

       A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

    (h)

      

    [ ]

       A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i)

      

    [ ]

       A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j)

      

    [ ]

       A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

    (k)

      

    [ ]

       Group, in accordance with §240.13d-1(b)(1)(ii)(K).

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4.

    Ownership **


    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)

    Amount Beneficially Owned **

    North Tide Capital Master, LP – 760,069 shares

    North Tide Capital GP, LLC – 760,069 shares

    North Tide Capital, LP – 760,069 shares

    North Tide Capital, LLC – 760,069 shares

    Conan Laughlin – 760,069 shares

     

      (b)

    Percent of Class **

    North Tide Capital Master, LP – 5.5%

    North Tide Capital GP, LLC – 5.5%

    North Tide Capital, LP – 5.5%

    North Tide Capital, LLC – 5.5%

    Conan Laughlin – 5.5%

     

      (c)

    Number of shares as to which such person has:**

     

      (i)

    sole power to vote or to direct the vote

    North Tide Capital Master, LP – 0 shares

    North Tide Capital GP, LLC – 0 shares

    North Tide Capital, LP – 0 shares

    North Tide Capital, LLC – 0 shares

    Conan Laughlin – 0 shares

     

      (ii)

    shared power to vote or to direct the vote

    North Tide Capital Master, LP – 760,069 shares

    North Tide Capital GP, LLC – 760,069 shares

    North Tide Capital, LP – 760,069 shares

    North Tide Capital, LLC – 760,069 shares

    Conan Laughlin – 760,069 shares

     

      (iii)

    Sole power to dispose or to direct the disposition of


    North Tide Capital Master, LP – 0 shares

    North Tide Capital GP, LLC – 0 shares

    North Tide Capital, LP – 0 shares

    North Tide Capital, LLC – 0 shares

    Conan Laughlin – 0 shares

     

      (iv)

    shared power to dispose or to direct the disposition of

    North Tide Capital Master, LP – 760,069 shares

    North Tide Capital GP, LLC – 760,069 shares

    North Tide Capital, LP – 760,069 shares

    North Tide Capital, LLC – 760,069 shares

    Conan Laughlin – 760,069 shares

     

    **

    Shares reported herein for the General Partner, the Investment Manager and the Fund General Partner represent Common Stock beneficially owned and held of record by the Fund for which the Investment Manager serves as the Investment Manager and the Fund General Partner serves as general partner. The General Partner serves as the sole general partner of the Investment Manager. Shares reported herein for Mr. Laughlin represent Common Stock beneficially owned and held of record by the Fund. Mr. Laughlin is the sole manager of the General Partner and the Fund General Partner.

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    Not applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group

    Not applicable.

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Exhibits    Exhibit
    99.1    Joint Filing Agreement by and among the Reporting Persons.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 16, 2021

     

    NORTH TIDE CAPITAL MASTER, LP

    By: North Tide Capital GP, LLC,

    its General Partner

    By:  

    /s/ Conan Laughlin

      Conan Laughlin
      Manager
    NORTH TIDE CAPITAL GP, LLC
    By:  

    /s/ Conan Laughlin

      Conan Laughlin
      Manager

    NORTH TIDE CAPITAL, LP

     

    By: North Tide Capital, LLC

    Its General Partner

    By:  

    /s/ Conan Laughlin

      Conan Laughlin
      Manager
    NORTH TIDE CAPITAL, LLC
    By:  

    /s/ Conan Laughlin

     

    Conan Laughlin

    Manager

    CONAN LAUGHLIN
    By:  

    /s/ Conan Laughlin

      Conan Laughlin
      Manager
    Get the next $IRIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IRIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IRIX
    Financials

    Live finance-specific insights

    See more
    • Iridex Reports First Quarter 2025 Financial Results

      MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 29, 2025. First Quarter 2025 Financial Highlights Total revenue was $11.9 million, compared to $11.8 million in the first quarter of 2024Cyclo G6® product family revenue was $3.2 million, an increase of 8% year-over-year, compared to $3.0 million in the prior year quarter Sold 13,900 Cyclo G6 probes compared to 13,300 in the prior year quarterSold 24 Cyclo G

      5/13/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex to Report First Quarter 2025 Financial Results on May 13, 2025

      MOUNTAIN VIEW, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the first quarter 2025 and provide a business update after the close of trading on Tuesday, May 13, 2025. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing conference ID: 698002. A live and re

      4/30/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex to Host Strategic Vision Call on April 16, 2025

      MOUNTAIN VIEW, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will host a special call on April 16, 2025 to introduce Iridex and Novel's strategic vision for the Company following Novel's recent strategic investment in Iridex. The Company's management team will host a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 888-596-4144 and providing conference ID: 9584140. A live an

      4/9/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Dizon Romeo R bought $1,451 worth of shares (1,305 units at $1.11), increasing direct ownership by 13% to 11,205 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/13/25 5:35:24 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Dizon Romeo R bought $116 worth of shares (100 units at $1.16), increasing direct ownership by 1% to 9,900 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/12/25 5:53:31 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Dizon Romeo R bought $115 worth of shares (100 units at $1.15), increasing direct ownership by 1% to 9,800 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/9/25 4:46:56 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Iridex Reports First Quarter 2025 Financial Results

      MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 29, 2025. First Quarter 2025 Financial Highlights Total revenue was $11.9 million, compared to $11.8 million in the first quarter of 2024Cyclo G6® product family revenue was $3.2 million, an increase of 8% year-over-year, compared to $3.0 million in the prior year quarter Sold 13,900 Cyclo G6 probes compared to 13,300 in the prior year quarterSold 24 Cyclo G

      5/13/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex to Report First Quarter 2025 Financial Results on May 13, 2025

      MOUNTAIN VIEW, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the first quarter 2025 and provide a business update after the close of trading on Tuesday, May 13, 2025. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing conference ID: 698002. A live and re

      4/30/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex Announces Preliminary Operational and Financial Results for the First Quarter 2025

      MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the first quarter ended March 29, 2025. First Quarter 2025 Results Total revenue is expected to be between $11.8 million and $12.0 million, compared to $11.8 million in the comparable quarter of 2024Sold approximately 13,900 Cyclo G6 probes, compared to 13,300 in the prior year quarterSold approximately 24 Cyclo G6 Laser Systems, compared to 22 in the

      4/14/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by IRIDEX Corporation

      SC 13D - IRIDEX CORP (0001006045) (Subject)

      11/23/22 4:57:01 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D filed by IRIDEX Corporation

      SC 13D - IRIDEX CORP (0001006045) (Subject)

      9/20/22 2:06:59 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by IRIDEX Corporation (Amendment)

      SC 13G/A - IRIDEX CORP (0001006045) (Subject)

      2/10/22 8:17:17 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    SEC Filings

    See more
    • SEC Form 10-Q filed by IRIDEX Corporation

      10-Q - IRIDEX CORP (0001006045) (Filer)

      5/13/25 4:43:02 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IRIDEX Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IRIDEX CORP (0001006045) (Filer)

      5/13/25 4:16:38 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEFA14A filed by IRIDEX Corporation

      DEFA14A - IRIDEX CORP (0001006045) (Filer)

      4/28/25 4:13:02 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Iridex with a new price target

      Roth Capital reiterated coverage of Iridex with a rating of Buy and set a new price target of $11.00 from $9.00 previously

      5/12/21 11:32:01 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Roth Capital reiterated coverage on IRIDEX with a new price target

      Roth Capital reiterated coverage of IRIDEX with a rating of Buy and set a new price target of $9.00 from $6.00 previously

      3/9/21 8:09:06 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Roth Capital reiterated coverage on Iridex with a new price target

      Roth Capital reiterated coverage of Iridex with a rating of Buy and set a new price target of $9.00 from $6.00 previously

      3/3/21 12:29:03 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Dizon Romeo R bought $1,451 worth of shares (1,305 units at $1.11), increasing direct ownership by 13% to 11,205 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/13/25 5:35:24 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Dizon Romeo R bought $116 worth of shares (100 units at $1.16), increasing direct ownership by 1% to 9,900 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/12/25 5:53:31 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Dizon Romeo R bought $115 worth of shares (100 units at $1.15), increasing direct ownership by 1% to 9,800 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/9/25 4:46:56 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Leadership Updates

    Live Leadership Updates

    See more
    • Iridex Appoints Patrick Mercer as Chief Executive Officer

      MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the appointment of Patrick Mercer as the Company's Chief Executive Officer and President effective October 1, 2024. Previously Mr. Mercer served as the Company's Chief Operating Officer and President. David Bruce, the Company's prior Chief Executive Officer, is transitioning from the Company. Coincident to Mr. Mercer's appointment, Scott Shuda was appointed Executive Chairman of the Company's board of directors. M

      10/3/24 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust

      MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse® Transscleral Laser Therapy (TLT) using Iridex' Cyclo G6® Laser and the MicroPulse P3® Delivery Device. This partnership establishes a large-scale enrollment platform to advance clinical research. David I. Bruce, President and CEO of Iridex, shared: "The first patient enrollment in this partnership with Imperial College Healthcare NHS Trust is the first step toward mu

      1/24/24 8:00:00 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex Announces the Appointment of Beverly Huss to its Board of Directors

      MOUNTAIN VIEW, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the appointment of Beverly Huss to its board of directors, effective, March 17, 2022. In connection with Ms. Huss' appointment to the board, the size of the board was increased from five to six members as of the Effective Date. "I am very pleased to welcome Beverly to our board of directors," said Scott Shuda, chairman of the board of Iridex. "Beverly's extensive management and board experience in the medical device industry and proven track record with non-invasive a

      3/21/22 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care